Abstract
Introduction

Systemic lupus erythematosis (SLE) is considered the archetypal systemic autoimmune disease, clinically characterized by multisystem involvement and varied serologic abnormalities. No two patients with SLE present or have disease that evolves in exactly the same way and the clinical picture of SLE is dictated by the relative contributions of the organs affected by the characteristic autoantibodies. For this reason, diagnostic criteria has been created by the American College of Rheumatology (ACR), which includes 11 categories, wherefrom four or more must be present to diagnose SLE (1). Haematological disorders form a part of these criteria and include thrombocytopenia, leukopenia and lymphopenia, and hemolytic anemia (1). Beyan et al carried out a study of haematological abnormalities in SLE patients and found that most of the patients had anemia at the time of presentation due to various etiologies (2). Anemia of chronic disease (46%) was the most common picture, with another 28% having hemolytic anemia. Leukopenia andisis because of fibrotic transformation of the bone marrow. It usually arises as a clonal disorder but can also be associated with SLE where the autoantibodies attack the marrow architecture, in which instance it is then termed autoimmune myelofibrosis (3)
.
mmol/L; serum creatinine -204 μmol/L). She was treated with intravenous antibiotics tazocin, teicoplanin and granulocyte colony stimulating factor (GCSF). GCSF failed to improve the neutrophil count. Although, the patient's dsDNA was negative, the presence of four clinical parameters including i) renal impairment, ii) serositis (pleural and pericardial effusions and ascites), iii) leucopoenia and thrombocytopenia, and iv) positive antinuclear antibody satisfied the ACR criteria for the diagnosis of systemic lupus erythematosus (SLE).
A Table 1 and Fig. 3 .
/ L; APTT -40 secs; FVIII -102%). A summary of the blood results during the different clinical presentations corresponding to the diagnoses of the three autoimmune conditions are given in
At present, almost four years later, she is maintained on mycophenolate mofetil and prednisolone (5 mg daily) as immunosuppressive agents. Her symptoms are now of lethargy and occasional bruising. Although she has not managed to resume a full time job, she does volunteer work in afterschool art classes. Her clotting screen is now normal and she is lupus anticoagulant and anti-cardiolipin antibody negative.
Discussion
SLE is a clinically heterogeneous disease demonstrated by the unusual presentation in this report. Because of the varied presentation, diagnostic criteria have been developed for this condition, which include clinical manifestations, alongside laboratory results (1). These criteria take into consideration several systemic manifestations including haematological abnormalities. Pancytopenia is rare in SLE but can be associated with myelofibrosis (5). Myelofibrosis can be classified as primary (clonal disorder of the bone marrow) when it is called idiopathic myelofibrosis and secondary, when it arises due to other pathological conditions (6). Secondary myelofibrosis is often found in association with malignancy and chronic infections like HIV and tuberculosis (7)
. It has also rarely been described with SLE and other autoimmune disorders, when it may be called autoimmune myelofibrosis (7, 8 Abbreviations: PT-prothrombin time; APTT -activated partial thromboplastin time; ALT -alanine aminotransferase; ITU -intensive care unit; WCC-white cell count; Plt -platelet count, N/A -not available.
T a b l e 1 . L a b o r a t o r y Da t a Co r r e s p o n d i n g t o t h e Cl i n i c a l P r e s e n t a t i o n o f t h e P a t i e n t
found in the examination of the bone marrow of our patient, which differs from that previously described in the literature.
The main treatment of SLE-associated autoimmune myelofibrosis is corticosteroids, which has demonstrated good clinical effects with resolution of the bone marrow fibrosis (7)
. In the present patient, the latter was not confirmed by a further trephine, however peripheral blood samples were correlated with a positive response in the bone marrow. Interestingly, fibrosis which is primarily reticulin based often responds to steroids. In contrast 'collagen fibrosis', occurring in idiopathic myelofibrosis, has been shown to be more refractory to steroid therapy (10 
F i g u r e 3 . F i g u r e d e t a i l i n g t h e c l i n i c a l c o u r s e o f t h e p a t i e n t . T h e c l i n i c a l c o u r s e i n d a y s i s c o r r e l a t e d wi t h t h e b l o o d r e s u l t s , d i a g n o s e s a n d ma n a g e me n t . Ab b r e v i a t i o n s : Hb : h e mo g l o b i n , WCC: wh i t e c e l l c o u n t , P T : p r o t h r o mb i n t i me , AP T T : a c t i v a t e d p a r t i a l t h r o mb o p l a s t i n t i me
VIII protein (9) . Inhibition of Factor VIII, which functions as a cofactor for Factor IXa in the enzymatic activation of Factor X, leads to a reduction in the generation of thrombin on the surface of activated platelets (13) . AH is a rare disorder with an estimated incidence of 1.48 cases per million a year in the UK (14) . Case series have shown that underlying diseases are identifiable in up to 50% of cases (15) (17) , recombinant factor VIIa (rFVIIa) (18) and factor eight inhibitor bypassing activity (19) . In this case, bleeding due to AH was controlled with rFVIIa. The exact mode of action of this agent is yet to be elucidated, but it is believed to generate local thrombin formation by enhancing the tissue factor/ FVIIa action at the site of injury, which then activates factors X and IX (20) . A cell-based model of haemostasis has indicated that high dose rFVIIa binds to activated platelets with a low affinity and activates factor X independently of tissue factor (21) .
In order to eradicate the factor VIII antibodies, it is also common practice to commence a form of immunosuppressive therapy. However, spontaneous remission has been observed with AH related to pregnancy and post-partum periods (22 
